SEARCH

SEARCH BY CITATION

References

  • 1
    Friedberg JW, Cohen P, Chen L et al. Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin’s lymphoma: results form a phase II multicenter, single-agent study. J Clin Oncol 2008; 26: 20410.
  • 2
    Rummel MJ, Al-Batran SE, Kim SZ et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin’s lymphoma. J Clin Oncol 2005; 23: 33839.
  • 3
    Robinson KS, Williams ME, Van der Jagt RH et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin’s lymphoma. J Clin Oncol 2008; 26: 44739.
  • 4
    Kahl BS, Bartlett NL, Leonard JP et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Results from a multicenter study. Cancer 2010; 116: 10614.
  • 5
    Ogura M, Taniwaki M, Ando K, et al. Phase I and pharmacokinetic study of bendamustine hydrochloride in relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010; 101: 20548.
  • 6
    Ohmachi K, Ando K, Ogura M, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci2010; 101: 205964.
  • 7
    Cheson BD, Horning SJ, Coiffier B et al. Report of international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 124453.
  • 8
    Jerusalem G, Hustinx R, Beguin Y, Fillet G. Evaluation of therapy for lymphoma. Semin Nucl Med 2005; 35: 18696.
  • 9
    Mikhaeel NG. Use of FDG-PET to monitor response to chemotherapy and radiotherapy in patients with lymphomas. Eur J Nucl Med Mol Imaging 2006; 33: 226.
  • 10
    Weiler–Sagie M, Bushelev O, Epelbaum R et al. 18F-FDG avidity in lymphoma readdressed: a study of 766 patients. J Nucl Med 2010; 51: 2530.
  • 11
    Tsukamoto N, Kojima M, Hasegawa M et al. The usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and a comparison of 18F-FDG-PET with 67gallium scintigraphy in the evaluation of lymphoma: relation to histologic subtypes based on World Health Organization classification. Cancer 2007; 110: 6529.
  • 12
    Elstrom R, Guan L, Baker G et al. Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 2003; 101: 38756.
  • 13
    Bodet-Milin C, Touzeau C, Leux C et al. Prognostic impact of (18)F-fluoro-deoxyglucose positron emission tomography in untreated mantle cell lymphoma: retrospective study form the GOELAMS groups. Eur J Nucl Med Mol Imaging 2010; 37: 163342.
  • 14
    Juweid ME, Stoobants S, Hoekstra OS et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of International Harmonization Project in lymphoma. J Clin Oncol 2007; 25: 5718.
  • 15
    Cheson BD, Pfistner B, Juweid ME et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 57986.
  • 16
    Fueger BJ, Yeom K, Czernin J, Sayre JW, Phelps ME, Allen–Auerbach MS. Comparison of CT, PET, and PET/CT for staging patients with indolent non-Hodgkin’s lymphoma. Mol Imaging Biol 2009; 11: 26974.
  • 17
    Fukukita H, Senda M, Terauchi T et al. Japanese guideline for the oncology FDG-PET/CT data acquisition protocol: synopsis of Version 1.0. Ann Nucl Med 2010; 24: 32534.
  • 18
    Haioun C, Itti E, Rahmouni A et al. [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 2005; 106: 137681.
  • 19
    Hutchings M, Loft A, Hansen M et al. FDG-PET after two cycles of chemotheraphy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 2006; 107: 529.
  • 20
    Gallamini A, Rigacci L, Merli F et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease. Haematologica 2006; 91: 47581.
  • 21
    Itti E, Lin C, Dupuis J et al. Prognostic value of interim F-18 FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009; 50: 52733.
  • 22
    Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR. FDG-PET after two or three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 2005; 16: 151423.
  • 23
    Gallamini A, Hitchings M, Rigacci L et al. Early interim-2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian–Danish study. J Clin Oncol 2007; 25: 374652.
  • 24
    Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50: 122S50S.